| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 0.69 | 96.7% | 97.6% |
| Total Income | 0.69 | 96.7% | 97.6% |
| Expenditure | 27.23 | 23.2% | 8.4% |
| PBT | — | ||
| Net Profit | -31.78 | 2955.8% | 1077.8% |
| OPM | — | ||
| NPM | — | ||
| EPS | -0.07 | 800.0% |
Lexicon Pharmaceuticals Reports Q2 2026 Financial Results and Provides Clinical Updates
06 Aug 2026 · 6 Aug, 5:08 pm
Summary
Lexicon Pharmaceuticals reported a net loss of $31.8 million for the second quarter of 2026, a shift from a net income of $3.3 million in the same period of 2025. Total revenues for the quarter were $0.7 million, a significant decrease from $28.9 million in Q2 2025, largely due to a reduction in licensing revenue. Research and development expenses increased to $17.4 million, while SG&A expenses also saw a slight rise. The company highlighted the completion of enrollment in its SONATA-HCM study and ongoing NDA resubmission activities for ZYNQUISTA®.
Key Highlights
- 1
Lexicon Pharmaceuticals reported total revenues of $0.7 million for the second quarter of 2026, primarily from net sales of INPEFA.
- 2
Total revenues for the second quarter of 2025 were $28.9 million, including $27.6 million in licensing revenue from the Novo Nordisk agreement.
- 3
Research and development expenses increased to $17.4 million in Q2 2026 from $15.7 million in Q2 2025, driven by the SONATA-HCM Phase 3 clinical trial.
- 4
Selling, general and administrative expenses rose to $9.8 million in Q2 2026 from $9.4 million in Q2 2025.
- 5
The company reported a net loss of $31.8 million, or $0.07 per share, for the second quarter of 2026, compared to a net income of $3.3 million, or $0.01 per share, in the prior year period.
- 6
As of June 30, 2026, Lexicon had $190.6 million in cash and investments, an increase from $96.2 million at the end of 2025, due to a stock sale.
- 7
Enrollment has been completed in the Phase 3 SONATA-HCM study, with top-line data expected in the first quarter of 2027.
Management Comments
Mike Exton
Lexicon continued to make strong progress during the second quarter, with the refinement of our strategy and sharpening of our focus beginning to bear fruit across our business. Among all the accomplishments, I’m particularly pleased that we have completed enrollment of our SONATA-HCM study on time, reflecting strong clinical interest for a novel class of medicine to treat HCM. Overall, I could not be more confident in how these opportunities are poised to shape the company over the coming months.
Scott Coiante
We remain very focused on disciplined, targeted capital allocation as we continue to advance our clinical programs. With early commercial planning now underway for our late-state pipeline, we are committed to maximizing the value of these opportunities to create long-term shareholder value.
Informational and educational content only. Not investment advice.